Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Tên lửa Kheibar Shekan của Iran và khả năng xuyên phá phòng không

Tên lửa Kheibar Shekan của Iran và khả năng xuyên phá phòng không

Thế giới
(Baothanhhoa.vn) - Trong bối cảnh căng thẳng quân sự giữa Mỹ và Iran tiếp diễn, tên lửa đạn đạo tầm trung Kheibar Shekan của Iran đang thu hút sự quan tâm của giới phân tích quân sự nhờ khả năng cơ động và đặc tính được cho là gây khó khăn cho các hệ thống phòng thủ tên lửa.
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh